Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Xencor (NASDAQ:XNCR) announced that its licensee for Ultomiris informed Xencor it believes no additional U.S. royalties are owed and does not intend future U.S. payments, while continuing ex-U.S. payments. Xencor said it will seek resolution and conservatively updated cash runway to mid-2028.
The company reiterated issuance of U.S. Patent 12,492,253 and had previously expected an estimated $100–$120 million aggregate in low single-digit royalties from Ultomiris U.S. sales through 2028. Xencor expects $380–$400 million in cash and equivalents at year-end 2026.
Xencor (NASDAQ:XNCR) reported Q4 2025 and full-year results, highlighted by $610.8M in cash at year-end, Q4 revenue $28.2M and full-year revenue $125.6M. The company advanced multiple clinical programs including XmAb819 dose-expansion, XmAb942 Phase 2b enrollment, and plans for XmAb412 first-in-human in 2H26.
Guidance: Xencor expects year-end 2026 cash of $400–$430M and sufficient resources to fund operations through 2028. The company also estimates potential Xtend royalty revenue of $100–$120M through 2028.
Xencor (NASDAQ:XNCR) management will present at three investor conferences in early March 2026: TD Cowen on March 2, Leerink Partners on March 10, and Barclays on March 11.
Presentation times are listed in ET and PT. Live webcasts will be available under Events & Presentations on the company website, with replays accessible for at least 30 days.
Xencor (NASDAQ:XNCR) outlined 2026 corporate priorities and clinical milestones across five wholly owned XmAb® clinical-stage candidates. Key clinical readouts planned in 2026 include new data to support recommended Phase 3 doses for XmAb819 and XmAb541 in 2H26, Phase 1 updates for plamotamab and XmAb657 in 2H26, final Phase 1 healthy-volunteer results for XmAb942 in 1H26, and a first-in-human study start for XmAb412 in 2H26. Prior clinical results cited: XmAb819 showed a 25% partial response rate (20 evaluable patients) and a 70% disease control rate. Xencor ended Q4 2025 with approximately $611 million in unaudited cash, cash equivalents and marketable debt securities, which the company expects will fund operations through 2028.
Xencor (NASDAQ:XNCR) announced issuance of U.S. Patent 12,492,253 covering its Xtend™ Fc domain for C5-targeting antibodies, extending the U.S. patent term into December 2028—about three years longer than the prior latest-to-expire U.S. Xtend patent. Xencor expects to receive low-single-digit royalties on U.S. sales of Ultomiris (ravulizumab-cwvz) through December 2028.
The company estimates an additional $100–$120 million of potential royalty revenue for the extended term based on consensus Ultomiris sales forecasts. OMERS acquired royalties with annual caps up to $35 million for 2026–2028. Xencor recognized $51.0 million of non-cash royalty revenue for the nine months ended September 30, 2025.
Xencor (NASDAQ:XNCR) announced management will participate in two investor conferences in late 2025: the TD Cowen Immunology and Inflammation Virtual Summit on Wednesday, November 12, 2025 at 3:00 p.m. ET / 12:00 p.m. PT, and the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 p.m. ET / 11:00 a.m. PT.
Both presentations will be available via live webcast under the company’s Investors & Events section at www.xencor.com. Replays will be posted on the Xencor website for at least 30 days after the events.
Xencor (NASDAQ:XNCR) reported third quarter 2025 results and clinical updates on November 5, 2025. Q3 revenue was $21.0M vs $17.8M year-ago. Cash, cash equivalents and marketable debt securities were $633.9M at September 30, 2025 and the company expects to end 2025 with $570M–$590M, providing runway into 2028. Net loss was $6.0M, or $(0.08) per share, versus $(0.72) in Q3 2024. Other income increased to $41.5M driven by unrealized gains.
Clinical: XmAb819 and XmAb541 showed early anti-tumor activity with planned recommended Phase 3 dose selection in 2026 and pivotal study starts in 2027; XmAb942 and plamotamab advanced into Phase 2b and Phase 1b studies, respectively.
Xencor (NASDAQ:XNCR) reported initial Phase 1 data for XmAb819, an ENPP3 x CD3 T-cell engager in development for advanced clear cell renal cell carcinoma (ccRCC), with results current as of Sept 19, 2025. Across 69 patients in 10 IV and 5 SC cohorts, XmAb819 showed a 25% overall response rate (5/20) and a 70% disease control rate (14/20) within the preclinically predicted target dose range. Safety was generally tolerable; common TEAEs included CRS, rash and GI events, mostly Grade 1–2. Notable safety signals: Grade 3 rash 16%, Grade 3 liver enzyme elevations 7%, one Grade 4 DLT (elevated liver enzymes), and no ICANS or Grade 5 events. Dose-expansion is underway and a recommended Phase 3 dose is expected to be selected during 2026.
Xencor (NASDAQ:XNCR) will host a live webcast and conference call on Friday, October 24, 2025 at 1:30 p.m. ET to discuss initial results from the ongoing Phase 1 dose‑escalation study of XmAb819, an ENPP3 x CD3 T‑cell engaging bispecific antibody for advanced clear cell renal cell carcinoma (ccRCC).
The same data will be presented as a poster at the AACR‑NCI‑EORTC Conference in Boston during Poster Session B on October 24, 12:30–4:00 p.m. ET (poster title: “Preliminary Phase 1 safety and antitumor activity of XmAb819…in patients with advanced ccRCC”).
The webcast is available via the company investor website and a recording will be posted for at least 30 days.
Xencor (NASDAQ:XNCR) will present initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3 bispecific) in patients with advanced clear cell renal cell carcinoma (ccRCC) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
The poster (Session: Poster Session B) is scheduled for Friday, October 24, 2025, 12:30–4:00 p.m. ET. Xencor submitted a placeholder abstract based on a prior data cut; full conference abstracts are due October 22, 2025 at 12:00 p.m. ET. An updated dataset with detailed safety analysis and efficacy from the target dose range will be presented when the conference embargo lifts. Management will host a webcast and conference call to discuss results; access details will be provided later.